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ABSTRACT 
INTRODUCTION: Several studies have shown an association of anti-C1q antibodies 
(abs) with systemic lupus erythematosus (SLE) nephritis and disease activity. The aim of 
this study is to determine the relevance of the anti-C1q abs and the C1q levels, in Black 
South Africans with SLE and their relevance to disease activity and/or organ damage, 
specifically renal disease.  
METHODS: Serum anti-C1q abs and C1q levels were measured in 96 SLE patients who 
were also assessed for disease activity, using the SELENA Systemic Lupus Erythematosus 
Disease Activity Index (SLEDAI), and organ damage as measured by the Systemic Lupus 
International Collaborating Clinics/American College of Rheumatology (SLICC) Damage 
Index. Furthermore patients were assessed for the presence of an active urine sediment as 
evidenced by otherwise unexplained proteinuria, haematuria or cellular casts. Serum anti-
C1q abs was measured by a commercial Elisa kit and serum C1q by 
immunoelectrophoresis.  
RESULTS: Of the 96 patients; the majority, 87 were female (90.65%), with a mean (SD) 
age and disease duration (SD) of 38.1 (13.0) years and 4.2 (4.4) years respectively. An 
active urine sediment was found in 21 (21.88%) patients. Elevated anti-C1q abs were 
present in 12 (12.50%) of the patients and 7 (14.29%) of the patients with renal 
involvement. Serum anti-C1q abs levels correlated significantly with SELENA SLEDAI 
scores (p=0.004, r =0.41).Anti-C1q abs levels were significantly higher in patients with an 
active urine sediment (p= 0.007). C1q levels were decreased in 17/96 (17.71%) patients 
and 11/49 (22.45%) patients with renal involvement. No associations with any other 
clinical features were observed. 
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CONCLUSION: The findings indicate that in Black South Africans with SLE, although 
elevated anti-C1q abs levels were present in only a small minority of patients, the abs were 
associated with SLE global activity as determined by the SELENA SLEDAI and to the 
presence of an active urine sediment. These findings suggest that anti-C1q abs are a 
potential bio-marker of disease activity, especially active renal disease. 
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Chapter 1.  INTRODUCTION 
1.1 History of systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder, which is 
associated with an excess of autoantibodies. The disease is the result of a complex 
interaction of genetic factors, autoantibodies, hormones and environmental factors 
(Isenberg, 1997) . Tissues and cells are damaged by the deposition of pathogenic 
autoantibodies and immune complexes, any organ system may be affected and the disease 
may be easily confused with a variety of infectious, inflammatory, malignant or metabolic 
disorders  
Although SLE is widely recognized today, initial descriptions probably go back as far as 
Hippocrates (~400BC) and Paracelcus (~1500AD). The word lupus (Latin for wolf) itself 
was first used to describe certain skin lesions which had the appearance of having been 
caused by the gnawing of a wolf, after the fall of the Roman Empire. One of the earliest 
reports is from 916 A.D. in the description of Eraclius, Bishop of Liege, at the shrine of St. 
Martin in Tours  (Smith and Cyr, 1988). Subsequently the term 'Lupus Erythemateux' was 
coined in the 1850s by the Parisian physicians Cazenave and Clausit in Paris, at the Saint 
Louis Hospital for skin diseases (Wallace and Lyon, 1999). 
Moriz Kaposi was the first physician to recognize more than just the skin disease among 
patients with SLE, when in a 1872 article he stated that “grave and even dangerous 
constitutional symptoms may be intimately associated with the process in question (lupus 
erythematosus), and that death may result”.  
The first mention of SLE as we know it was by Sir William Osler in 1895, when he 
described 29 young ladies with skin rashes and chest pain from inflammation of the lining 
of the lung (pleurisy) or heart (pericarditis). These patients also had kidney disease, 
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strokes and brain involvement severe enough to be fatal, so that the majority had 
succumbed to their disease within two years (Osler, 1976). 
During the passage of the twentieth century, several revolutionary immunological 
phenomena were described in SLE, sparked by Hargraves’ discovery of the LE cell in 
1948, which set the stage for the study of serology among SLE patients. This culminated 
in the discovery of the lupus anticoagulant by Conley and Hartman in 1952, and 
antinuclear antibodies (ANA) by Miescher and Fauconnet in 1954 (Wallace and Hahn, 
2002). All this has led to the description of the disease as we know it today, yet the 
diagnosis of SLE can still be as challenging as ever. 
 
1.2 Epidemiology  
1.2.1 Global overview of SLE 
SLE is predominately a disease of women in their reproductive years; it has a peak age of 
onset between the late teens and early 40s, and a female to male ratio of 9:1 (Wallace and 
Hahn, 2002). The disease occurs worldwide in all population groups, however the 
prevalence varies between racial groups and between countries, with most studies 
indicating that the incidence is highest in individuals with African or Asian ancestry. 
The incidence of SLE in the general population varies between 3.3 and 8.7/100 000 people 
(see Table 1) depending on the characteristics of the population being studied (i.e., age, 
gender, race, ethnic/national origin or period of time studied). 
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Table 1.1 – Incidence of SLE in selected countries 
Location Incidence* 
Iceland (Gudmundsson and Steinsson, 1990) 3.3 
United Kingdom (Hopkinson et al., 1993) 3.7 
Brazil (Vilar and Sato, 2002) 8.7 
* Incidence rates per 100 000 persons per year, including men and women. 
Prevalence studies in the general population have also shown a marked variation from 12 
to 254 per 100 000 people (Wallace and Hahn, 2002). This variability may be due to the 
factors listed above, or from methodological differences in case ascertainment and 
socioeconomic factors. However, true geographical differences cannot be dismissed and 
may result from disparities in genetic or environmental factors. 
Not only are there marked differences in the incidence and prevalence rates, but there 
appears to be true inter-ethnic variances in the clinical expression of SLE. Patients of 
African origin have a higher prevalence of discoid lupus and lupus nephritis (Cooper et al., 
2002). 
 
1.2.2 SLE in Africa 
There is currently no published data on the occurrence rates of SLE in South Africa. It was 
previously thought to occur less frequently in sub-Saharan African, due to the high 
prevalence of tropical infectious diseases, particularly malaria. Further confounding issues 
are the extremely poor access to skilled medical care, resulting in the under diagnosis and 
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under reporting in most of sub-Saharan Africa. Nevertheless, several studies have shown 
that patients of African extraction are at a greater risk of developing severe organ 
involvement, especially renal (Alarcon et al., 2001, Barr et al., 2003, Korbet et al., 2007). 
A study  looking at mainly Black South African (BSA) at Chris Hani Baragwanath 
Hospital, showed that renal involvement was the only independent predictor for a fatal 
outcome in South African SLE patients (Wadee et al., 2007). 
 
1.3 Aetiology and pathophysiology 
The exact aetiology of SLE remains unknown. SLE occurs in a genetically susceptible 
individual, who is exposed to a combination of environmental and hormonal factors. The 
genetic susceptibility has been evident from the familial clustering of cases and the high 
monozygotic twin concordance rate; whilst increased oestrogenic activity likely plays a 
role, hence the higher rates in women (Watts et al., 2009). The most consistent 
environmental component is the exposure to ultra violet light, which is known to worsen 
both cutaneous and systemic disease (Watts et al., 2009).  Furthermore, exposure to a large 
number of viral infections has been investigated as infectious triggers, although none have 
been conclusively implicated. 
What is known with certainty is that SLE is a multi-systemic autoimmune disease 
categorized by the production of various autoantibodies and immune complex deposition. 
A long standing plausible explanation for the autoantibodies found in SLE has been the 
aptly named ‘waste-disposal hypothesis’ (Pickering et al., 2000). This hypothesis is based 
on the observation that many of the auto antigens found in SLE, are found on the surface 
of apoptotic cells (AC) and that impaired clearance of AC is observed in experimental 
models of SLE. It is this inefficient clearance of AC that provides the almost limitless 
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antigenic potential for the development of autoantibodies. AC are usually cleared away by 
the complement system (Lu et al., 2008), which is a complex protein cascade serving a 
role in the host defence as well as clearance of immune complexes and AC.  
 
1.3.1 Autoantibodies in SLE 
The clinical diverse presentation of SLE is only surpassed by the number of 
autoantibodies described in this condition. There are well over a 100 autoantibodies 
described, the number steadily increasing each year. ANA are antibodies (abs) developed 
against nuclear self-antigens and are almost universal in SLE, their absence making the 
diagnosis doubtful (Zwart et al.). Autoantibodies in SLE can be broadly divided into 3 
groups, dependent on the antigen they are directed against; those against nuclear antigens 
like anti-double stranded DNA (dsDNA), those against serum proteins like anti-
complement factor 1q (anti-C1q), and those against membrane phospholipids, like 
anticardiolipin abs. Apart from the diagnostic value of the ANA, which is positive in over 
95% of patients with SLE (Fernando and Isenberg, 2005), several of the abs aid in 
evaluating organ specific SLE disease. 
Anti-dsDNA abs are present in about 60% of patients (Fernando and Isenberg, 2005), are 
highly specific for SLE and are considered to be the best predictors of a renal flare 
(Bootsma et al., 1997, Linnik et al., 2005), while several other abs are present in 
significantly lower numbers of patients (see Table 1.2). 
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Table 1.2 – Significances of antibodies in SLE (Watts et al., 2009). 
Antibody Target Prevalence in SLE Clinical Association 
Smith (Sm) ~5%(Caucasian) 
~40%(Afro-Caribbean) 
Vasculitis, CNS lupus. 
Ro ~40% Photosensitivity, rashes &congenital 
heart block. 
La ~15 Sjogren’s 
U1 RNP ~30% Raynaud’s phenomenon 
 
What has also been clearly shown, is that the prevalence of these autoantibodies has an 
ethnic variability. A study done at our centre showed that BSA with SLE had a higher 
prevalence of anti-Sm and anti- ribonucleoprotein (RNP) abs, a finding similar to that 
found in African-Americans and Afro-Caribbeans (Tikly et al., 1996).  
 
1.3.2 The Complement System 
The complement system is a group of over 20 biologically active proteins, mostly 
produced in the liver, named after its function to “complement” abs in the defense against 
microbial infection. Consequently, it serves an important function in host defense; 
however uncontrolled activation can result in tissue injury, as is the case in autoimmune 
diseases like SLE. 
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 The complement system can be activated via 3 separate pathways namely, the classic 
pathway, the alternative pathway and the lectin pathway.  The classical pathway is  
predominantly activated via the binding of immune complexes to complement factor 1q 
(C1q) (Reid, 1986). This binding causes sequential activation and amplification of other 
complement factors ultimately leading to the formation of a membrane attack complex; 
the function of which is to create a pore in the microbial cell wall causing lysis (Fig 1.1).   
 
Figure 1.1 The Complement Pathway.                        (Source, Wikipedia - 
http://en.wikipedia.org/wiki/Alternative_complement_pathway )    
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1.3.3 Structure and function of C1q 
C1q is a 460 kDa molecule that comprises of six subunits. Each subunit comprises of three  
polypeptide chains – A, B, and C, each chain in turn comprising of 3segments; a collagen 
like region, a triple helix region and a carboxy-terminal globular head. The six subunits 
are brought together into a 3 dimensional structure that resembles a bunch of tulips (Fig 
1.2). 
 
Figure 1.2 Structure of C1q (Lu et al., 2008). 
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Under normal physiological conditions, free C1q is not found. Rather, it exists as part of a 
larger complex – the C1qrs complex; consisting of 1 C1q molecule and 2 molecules each 
of the serine esterases C1r and C1s. The initial activation step is the binding of immune 
complexes to two or more of the globular head regions of C1q within the C1qrs complex. 
This results in a conformational change in the C1qrs complex, leading to the activation of 
the serine esterases C1r and C1s and subsequently activation of the rest of the cascade. 
Furthermore, C1q is instrumental in the removal of AC. This can be accomplished via 2 
mechanisms; directly or indirectly via complement activation (Lu et al., 2008). C1q binds 
to calreticulin in the surface blebs on AC, but not onto normal cells, thus opsonizing the 
AC for enhanced phagocytosis (Korb and Ahearn, 1997). Via this mechanism C1q directly 
opsonizes the AC, without the activation of complement. 
Alternatively, C1q can cause opsonization via complement activation. This occurs when 
polyclonal IgM binds to AC and then recruits C1q, with the subsequent activation of the 
classic complement pathway (Zwart et al., 2004). This may also occur with C-reactive 
protein binding to phosphorylcholine on AC, then recruiting C1q and the subsequent 
complement activation (Kim et al., 2003). 
 
1.3.4 History of anti-C1q antibodies  
During the 1970s, several tests were developed to measure immune complexes in diseases 
in which it was thought they played an important role. Of importance in the field of SLE, 
one of these tests was the solid phase C1q-binding assay; done by incubating the sera of 
SLE patients in plates coated with C1q (Agnello et al., 1971). In addition to binding 
immune complexes, it was subsequently shown that non-complexed IgG from the serum 
of SLE patients could also bind to the solid-phase C1q (Antes et al., 1988). This discovery 
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paved the way for the test to be specifically adapted to measure the levels of serum anti-
C1q abs.  As simple assays to detect anti-C1q abs have become available, they have been 
used in SLE and several other autoimmune conditions. 
Anti-C1q abs have been detected in Felty’s syndromre, rheumatoid vasculitis and 
hypocomplementeamic urticarial vasculitis syndrome (Pickering and Botto, 2010).  Thus 
anti-C1q abs have shown a low specificity for a particular disease.  
In SLE, several different sub-classes of  IgG anti-C1q abs have been found, although no 
clinical differences between the classes  have so far been reported (Schaller et al., 2009). 
Anti-C1q abs have been found in renal autopsy specimens from SLE patients with 
proliferative renal disease, at up to 50 fold greater concentrations than serum 
concentrations (Mannik and Wener, 1997). They have been shown to correlate with active 
proliferative lupus nephritis and most studies suggest that severe lupus nephritis is 
improbable in the absence of anti-C1q abs (Trendelenburg et al., 2006, Trendelenburg et 
al., 1999). Furthermore, anti-C1q abs are associated with hypocomplementaemia, 
especially with low levels of C1q, C3 and C4 (Siegert et al., 1991). Finally, hereditary C1q 
deficiency has been reported to be the greatest hereditary risk factor for the development 
of SLE (Schejbel et al., 2011). 
 
1.3.5 Pathogenicity of anti-C1q antibodies 
The mechanisms that cause immunogenicity of self antigens has not been fully elucidated. 
The most plausible explanation for the autoantibodies found in SLE has been the aptly 
named waste-disposal hypothesis (refer to pathogenesis). Taking into consideration this 
hypothesis, serum C1q would bind to early AC. Once bound, a conformational change 
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would occur in the C1q molecule, exposing a neoepitope. In a susceptible host, the 
impaired clearance of the C1q bound apoptotic cell, would lead to uptake of both into an 
antigen presenting cell. This process leads to the generation of autoantibodies against the 
apoptotic cell surface antigens, including C1q (Pickering and Botto, 2010). If this is 
superimposed onto the kidney during renal inflammation, immune complexes and 
apoptotic renal cells provide the binding sites for C1q. Once bound, C1q then attracts anti-
C1q abs that amplify the complement pathway resulting in tissue damage and renal injury. 
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1.4 Aim of the study 
The primary objective of the study was to determine the prevalence of the anti-C1q abs in 
BSA with SLE and the secondary objectives was to determine their clinical utility by 
examining their relationship to SLE disease activity and organ damage, specifically as a 
possible indicator for renal disease.
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Chapter 2.  PATIENTS AND METHODS 
2.1 Study population 
The study population comprised of 96 consecutive consenting BSA patients with SLE who 
were enrolled from the Connective Tissue Disease Clinic of the Chris Hani Baragwanath 
Hospital, Soweto. All patients were on optimal medical therapy. The patients were 
matched 1:1 for renal versus non-renal SLE involvement. Renal involvement was defined 
as fulfilling the renal criteria of the 1997 American College of Rheumatology (ACR) 
classification for SLE (Hochberg, 1997) at any point in the patient disease course. All 
patients were older than 18 years of age at disease onset and met the 1997 American 
College of Rheumatology (ACR) criteria for the classification of SLE (APPENDIX A).  
Informed consent was obtained from every subject. This study was approved by the 
University of the Witwatersrand Human Research Ethics Committee (APPENDIX B). 
2.2 Clinical assessment 
Clinical features were defined according to the 1997 ACR criteria; while autoantibody 
serology and complement levels were extracted from the clinical notes. An active urine 
was defined as the presence of an otherwise unexplained active urine sediment (cellular 
cast – red cell, haemoglobin, granular, tubular or mixed cast) or proteinuria  (ACR., 2006). 
All patients were assessed for disease activity, as measured by the SELENA Systemic 
Lupus Erythematosus Disease Activity Index (SLEDAI) (Petri et al., 1999); and organ 
damage as measured by the Systemic Lupus International Collaborating Clinics/American 
College of Rheumatology (SLICC) Damage Index (Gladman et al., 1996) (APPENDIX C 
and D). The SLEDAI and SLICC are 2 validated instruments used in the monitoring of 
patients with SLE (Griffiths et al., 2005). 
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2.3 Laboratory investigations 
2.3.1 Serum Analysis 
Serum was separated from a 5ml clotted blood sample and was stored at -20 degrees 
Celsius. All samples were then tested for anti-C1q abs by a commercial available enzyme 
linked immunoassay (ELISA) (Orgentec, Mainz, Deutschland). Concentrations of greater 
than or equal to 19 U/mL was considered positive. Samples that were found to be positive 
by ELISA were confirmed by Western blot using the complete C1q molecule under 
reducing conditions (Martensson et al., 1992). Serum C1q was measured as a percentage 
of normal by immunoelectrophoresis, accepting 78 to 131% as the normal; using an in-
house rabbit-anti-C1q antiserum. The above tests were performed at the Clinical 
Immunology and Transfusion Medicine Laboratory, Laboratory Medicine Skåne, in Lund, 
Sweden. 
 
2.4 Statistical Methods 
Data was captured onto a Microsoft Excel spread sheet and then analysed using GraphPad 
InStat (version 3) software and  Statistica Version 10.To compare continuous variables 
between groups,  the 2 tail Student’s t-test was used for normally distributed data and the 
Mann Whitney U test for non-normally distributed  data, while the Spearman’s correlation 
test was used to test the correlation of continuous variables. Categorical variables were 
analysed by the Chi-square test or the two-tailed Fisher’s exact test where indicated.        
A p-value of <0.05 was considered significant. 
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Chapter 3.  RESULTS  
3.1 Demographic and clinical features of SLE patients 
As shown in Table 1, 90% of the patients were females with a mean age and disease 
duration of  38.1 and 4.2 years, respectively. The commonest extra-renal features in the 
overall group were arthritis in 59.4% and discoid lupus in 55.2% of patients. All patients 
were ANA positive and the most common lupus specific autoantibody was the anti-Sm 
abs in 52.1% of patients.  
There were no significant differences in the clinical features between the renal and non-
renal groups. However, the renal group had a higher prevalence of anti-dsDNA abs and 
C3/C4 hypocomplementaemia (either or both C3 or C4, at the closest time point to study 
enrolment), as well as higher mean SLEDAI scores, driven largely by the presence of an 
active urine sediment. As expected when correlating the SLEDAI scores and SLE disease 
duration, a correlation was found (p<0.0001) as shown in figure 3.1. 
Of the 49 patients with renal disease, 41 patients had renal histology available. As shown 
in table 3.2, the most common histological subtype was Class V lupus nephritis (Weening 
et al., 2004) occurring in almost 35% of patients. There was no statistical difference in 
C1q or anti-C1q abs levels between histological subtypes. 
 
  
 
 
 
 
 
16 
Table 3.1 Clinical and serological features of renal versus non-renal groups. 
 
NS = not significant. 
n= number of individuals with feature. 
 
Feature Total(n=96) Renal 
(n=49) 
Non-Renal 
(n=47) 
p 
value 
Female sex 87 (90.7%) 44 (89.8%) 43 (91.5%) NS 
Age (years)-mean (SD) 38.1 (13.0) 35.7 (13.0) 40.7 (12.7) NS 
Disease (years) -mean (SD) 4.2(4.4) 4.5 (4.6) 4.0 (4.4) NS 
Malar rash  37 (38.5%) 17 (34.7%) 20 (42.6%) NS 
Discoid lupus  53 (55.2%) 25 (51.0%) 28 (59.6%) NS 
Oral ulcers  21 (21.9%) 10 (20.0%) 11 (23.4%) NS 
Photosensitivity 38 (39.6%) 19 (38.8%) 19 (40.4%) NS 
Arthritis  57 (59.4%) 25 (51.0%) 32 (68.1%) NS 
Serositis  11 (11.5%) 7 (14.3%) 4 (8.5%) NS 
Neurological disease 8 (8.3%) 4 (8.2%) 4 (8.5%) NS 
ANA positive 96 (100%) 49 (100%) 47 (100%) NS 
Anti-dsDNA abs positive 30 (31.3%) 22 (44.9%) 8 (17.0%) 0.01 
Anti-Sm abs positive 50 (52.1%) 24 (49%) 26 (55.3%) NS 
Anticardiolipin abs positive 14 (14.6%) 9 (18.4%) 5 (10.6%) NS 
C3/C4 Hypocomplementaemia 17 (17.7%) 11 (22.5%) 3 (6.4%) 0.02 
SLEDAI - mean (SD) 2.7 (5.6) 4.6 (7.2) 0.8 (1.8) 0.0006 
SLICC - mean (SD) 0.7 (0.8) 0.7 (0.9) 0.6 (0.8) NS 
Active Urine Sediment - no. of 
patient (%) 
21 (21.9%) 21 (42.9%) 0  
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Table 3.2  Histological classes of  lupus nephritis. 
 
Table 3.3 Serum analysis of renal versus non-renal groups. 
NS = not significant. 
n= number of individuals with feature 
Class of Lupus Nephritis 
(Weening et al., 2004) 
Total(n=49) 
Class I 0 
Class II 4 (8.2%) 
   Class II/V 3 (6.1%) 
Class III 12 (24.5%) 
   Class III/V 2 (4.1%) 
Class IV 3 (6.1%) 
Class V 17 (34.7%) 
Class VI 0 
No Data 8 (16.3%) 
Feature Total(n=96) Renal 
(n=49) 
Non-Renal 
(n=47) 
p 
value 
Anti-C1q Abs positive -no. of 
patients (%) 
12(12.5%)  7(14.3%)  5(10.6%) NS 
Anti-C1q (U/mL)- mean (SD)                                                                                                            10.7(14.2) 12.4(16.5) 9.0(11.1) NS
Low C1q Level - no. of patients 
(%) 
17(17.7%) 10(20.4%) 7(14.9%) NS 
C1q (% of normal) -mean (SD) 109.8%(41.4) 106.0%(56.1) 106.8%(30.1) NS 
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Figure 3.1 Scatterplot of SLEDAI score versus disease duration. 
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3.2 Clinical and laboratory correlates with anti-C1q abs 
3.2.1 Comparison between serum anti-C1q abs levels and urine sediment 
There was no significant difference in either anti-C1q abs positivity or titres between the 
renal and non-renal groups (see Table 3.3). Importantly however, the subgroup of renal 
patients with an active urine sediment had significant higher abs titres compared to the rest 
of the patients (mean (SD) = 18.37 (22.77) U/mL in the active urine sediment group 
versus a mean (SD) = 8.54 (9.79) U/mL in the remainder of the patients, p=0.007, see fig 
3.2). Similarly the frequency of the abs was significantly higher in the active urine 
sediment group (5/21 in the active urine sediment group versus 7/75 in the remainder of 
the patients, p=0.045). 
 
Figure 3.2 Anti-C1q abs levels versus urine sediment. 
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3.2.2 Correlation between anti-C1q abs and serum C1q levels 
Overall C1q levels were low in 17.7% of the patients, with no apparent differences 
between the groups (see Table 3.3).  Moreover, C1q levels were not significantly different 
between patients with an active urine sediment and the rest of the patients (mean (SD) = 
114.76 (65.11) % in the active urine sediment group versus a mean (SD) = 108.07 (31.25) 
% in the remainder of the patients, p=0.51).  No significant clinical or serological 
correlations, except for the weak correlation with anti-C1q abs (fig3.3), were observed 
with serum C1q levels. 
 
Scatterplot: Anti-C1q (U/mL) v s. C1q (% of  normal) (Casewise MD deletion)
C1q (% of  normal) = 116.34 - .6364  * Anti-C1q (U/mL)
Correlation: r = -.307451, p=0.03
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Figure 3.3 Scatterplot of C1q levels versus anti-C1q abs levels. 
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3.2.3 Correlation between serum anti-C1q abs levels and SLEDAI scores 
The anti-C1q abs levels correlated significantly with the SLEDAI scores (fig 3.4). There 
were no other significant correlations with any other clinical (except urine sediment) or 
serological features; or with the SLICC-DI and the anti-C1q abs levels. 
Scatterplot: Anti-C1q (U/mL) v s. 
SLEDAI
 (Casewise MD deletion)
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 = 1.0385 + .15620 * Anti-C1q (U/mL)
Correlation: r = .403829. p=0.004
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Figure 3.4 Scatterplot of anti-C1q abs levels versus SLEDAI scores. 
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Chapter 4.  DISCUSSION 
In this cross sectional study, anti-C1q abs were studied for their role in BSA with SLE, 
both for disease activity; in particular renal involvement, and disease damage.  
The patients that were included in the present study were similar demographically, 
clinically and serologically as those in a large retrospective study of SLE at the same 
institution (Wadee et al., 2007). The sex distribution of 9:1 is similar to that seen 
elsewhere in the world (Wallace and Hahn, 2002). 
The commonest clinical features were arthritis, occurring in almost 60% of patients, 
followed by discoid lupus in 55.2% of patients (see Table 3.1). Several studies have 
shown that discoid lupus is more common in Black Africans than in other population 
groups , in which it occurs in about 20% of patients (Wadee et al., 2007) (Cooper et al., 
2002).  
Since renal disease was a specific inclusion criterion in this study for half the patients, it is 
not possible to comment on its frequency in BSA based on the present study. However, 
nephropathy is a frequent complication occurring in up to 40% (Wadee et al., 2007) of 
patients in this population.  That C3/C4  hypocomplementaemia and raised anti-dsDNA 
abs were commoner in the renal group (see Table 3.1), is in keeping with the notion that 
lupus nephritis is due to immune complex deposition, of which anti-dsDNA abs are an 
important constituent, with complement consumption  (Bootsma et al., 1997, Fernando 
and Isenberg, 2005). 
The inverse relationship of the SLEDAI scores with disease duration is of interest. It is 
well known that with time, in most cases disease active declines, partly because of therapy 
but also due to the natural course of the disease.  
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 Overall, raised anti-C1q abs were found in only 14.2% of the 96 patients, with no 
statistical difference between the renal and the non-renal groups. The figure of 14.2% is 
numerically lower than reported in other studies, which have showed between  a third to 
half of patients having raised anti-C1q abs levels (Pickering and Botto, 2010). There was 
also no difference in the absolute level of the anti-C1q abs between the two groups. 
Furthermore as expected, Western blot of anti-C1q abs done on the anti-C1q abs positive 
ELISA  samples, were all are negative by Western blot; that is, do not bind any of 
separated C1q chains A, B or C (Martensson et al., 1992). 
Furthermore, it was also confirmed that the level of anti-C1q abs correlated with the 
overall level of disease activity as measured by the SLEDAI score, and more specifically 
with the presence of an active urine sediment (Figure 3.2), leading to an association with 
currently active renal disease. A study published recently has shown similar results, that 
the anti-C1q abs levels are a good marker of a renal flare (Akhter et al., 2011). 
As expected there was an inverse relationship between the level of anti-C1q abs and serum 
levels of C1q, which can easily be explained by the binding of the antibody to C1q with 
the subsequent consumption of C1q and deposition in the tissues. This is in keeping with 
previous reports (Siegert et al., 1991). 
Importantly, no correlation was found between the level of anti-C1q abs and other 
measured variables, especially the level of C3/C4 as previously reported (Isenberg et al., 
1997) (Cai et al., 2010). This may have been due to the type of test employed at our centre 
or a type II error because of the small sample size. 
Finally, there was a complete lack of association between C1q levels and disease activity.  
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4.1 Limitations of the study 
The cross sectional nature of the study did not allow for reporting on fluctuations in anti-
C1q abs levels and its relationship to disease activity over time. The reference values for 
both C1q and anti-C1q abs levels are based on those from  healthy European blood donors, 
which may be different from our population of BSA (Gould et al., 2006).  
Although most of the patients with renal involvement had a biopsy, this was not available 
in all cases, furthermore due to factors beyond our control the complement levels and C1q 
and anti-C1q abs levels with not all taken at precisely the same point in time. 
Finally, we did not look at the relationship of abs levels with corticosteroid / 
immunosuppressive therapy, which may have had an influence on the levels. 
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Chapter 5.  CONCLUSION  
The findings of this study are further evidence the anti-C1q abs may have an important 
role in the management of SLE patients. Although, elevated anti-C1q abs levels were 
present in only a small minority of patients, the findings indicate that in Black South 
Africans with SLE, anti-C1q abs were associated with SLE global activity as determined 
by the SELENA SLEDAI and more importantly, to the presence of an active urine 
sediment. These findings suggest that anti-C1q abs are a bio-marker of disease activity, 
especially active renal disease. 
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